GSE117620 resveratrol 1 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE117620_resveratrol_1_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE117620_resveratrol_1_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE117620_resveratrol_1_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE117620_resveratrol_1_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

long intergenic non-protein coding RNA 886

Gene

long intergenic non-protein coding RNA 273

Gene

OFD1 pseudogene 17

Gene

uncharacterized LOC101927253

Gene

RNA, 7SL, cytoplasmic 748, pseudogene

Gene

long intergenic non-protein coding RNA 2710

Gene

ribosomal protein L39 pseudogene 16

Gene

uncharacterized LOC105373742

Gene

PCBP2 pseudogene 4

  • Gene

    valyl-tRNA synthetase 1


  • Gene

    long intergenic non-protein coding RNA 886


  • Gene

    long intergenic non-protein coding RNA 273


  • Gene

    OFD1 pseudogene 17


  • Gene

    uncharacterized LOC101927253


  • Gene

    RNA, 7SL, cytoplasmic 748, pseudogene


  • Gene

    long intergenic non-protein coding RNA 2710


  • Gene

    ribosomal protein L39 pseudogene 16


  • Gene

    uncharacterized LOC105373742


  • Gene

    PCBP2 pseudogene 4

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.